The FDA approved Otarmeni (lunsotogene parvec-cwha), marking the first dual AAV vector-based gene therapy for genetic hearing loss treatment. The approval was granted under the National Priority Voucher Program.
The FDA approved Otarmeni (lunsotogene parvec-cwha), marking the first dual AAV vector-based gene therapy for genetic hearing loss treatment. The approval was granted under the National Priority Voucher Program.